- The Washington Times - Tuesday, October 15, 2002

NEW YORK Sam Waksal, the founder and former CEO of ImClone Systems Inc. and a friend of Martha Stewart's, was expected to plead guilty today to multiple charges in the company's insider-trading case, a law enforcement source told the Associated Press yesterday.
Mr. Waksal faces federal charges of securities fraud, perjury, bank fraud and obstruction of justice. The source, who requested anonymity, would not say to which charges Mr. Waksal was to plead guilty.
Waksal spokesman Scott Tagliarino, reached at his Connecticut home last night, declined to comment, as did a spokesman for the U.S. Attorney's office.
Mr. Waksal could face up to 30 years in prison if convicted of the most serious charge, bank fraud.
The former CEO was arrested June 12 on charges of trying to sell his ImClone shares and tipping off friends and family members after learning that the Food and Drug Administration would reject his company's experimental cancer drug, Erbitux. He was indicted in August and has pleaded not guilty.
Mrs. Stewart, an ImClone investor, sold almost 4,000 shares in the biotech company a day before the FDA's announcement in December that it would not approve the drug. That announcement caused ImClone's stock price to fall.
Mrs. Stewart has maintained that she had a prearranged order with her stockbroker, Peter Bacanovic, who was also Mr. Waksal's broker, to sell her shares if the stock dropped below a certain price. She has denied any wrongdoing and has not been charged.
An assistant at Merrill Lynch to Mr. Bacanovic, Douglas Faneuil, pleaded guilty this month to a misdemeanor charge of taking a payoff to keep quiet about Mrs. Stewart's sale of her shares. As part of his plea, Mr. Faneuil agreed to testify against Mrs. Stewart and others if they are charged in connection with the case.

Copyright © 2019 The Washington Times, LLC. Click here for reprint permission.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.


Click to Read More and View Comments

Click to Hide